Merck's IBD Drug From $10.8B Prometheus Deal Claims Its First Phase 3 Win

Merck’s Tulisokibart Met Primary and Key Secondary Endpoints in the Phase 3 ATLAS-UC Induction-only Study in Patients With Moderately to Severely Active Ulcerative Colitis (UC)

RAHWAY, N.J.--(BUSINESS WIRE)--Jun 22, 2026-

Merck's IBD drug from $10.8B Prometheus deal claims its first Phase 3 win

Merck’s $10.8 billion buyout of Prometheus Biosciences is showing its first signs of paying off. The lead program of that acquisition succeeded in its first Phase 3 trial, Merck said Monday morning, beating a placebo ...